Loading
A phase 2 trial of Atezolizumab, Fruquintinib in colorectal cancer, run by Kahr Bio Australia Pty Ltd, now recruiting.
A Study to Test DSP107 in Combination With Atezolizumab in Comparison With Fruquintinib as a New Treatment for Colorectal Cancer. is a phase 2 interventional study registered as NCT07235293 by Kahr Bio Australia Pty Ltd, with 90 participants planned, started 2026-01-16 and due to reach its primary completion in 2026-09-30. Interventions recorded: DSP107 + Atezolizumab, Fruquintinib. Conditions listed: Colorectal Cancer. No results are recorded here; the registry entry is the source.
Shares Fruquintinib, Anti-angiogenic therapy, Small-molecule kinase inhibitors, Immune checkpoint inhibitors.
Shares Fruquintinib, Anti-angiogenic therapy, Small-molecule kinase inhibitors.
Shares Fruquintinib, Anti-angiogenic therapy, Small-molecule kinase inhibitors, Colorectal cancer.
Shares Fruquintinib, Anti-angiogenic therapy, Small-molecule kinase inhibitors, Immune checkpoint inhibitors.
Shares Fruquintinib, Anti-angiogenic therapy, Small-molecule kinase inhibitors, Immune checkpoint inhibitors.
Shares Fruquintinib, Anti-angiogenic therapy, Small-molecule kinase inhibitors.
Shares Fruquintinib, Anti-angiogenic therapy, Small-molecule kinase inhibitors.
Shares Fruquintinib, Anti-angiogenic therapy, Small-molecule kinase inhibitors.